• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed by BioDelivery Sciences International Inc. (Amendment)

    2/10/23 4:14:56 PM ET
    $BDSI
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $BDSI alert in real time by email
    SC 13G/A 1 versor-bdsi123122a1.htm



     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION
    Washington, DC 20549

     

    SCHEDULE 13G/A

     

    Under the Securities Exchange Act of 1934

    (Amendment No. 1)*



    BioDelivery Sciences International, Inc.

    (Name of Issuer)

     

    Common stock, par value $0.001

    (Title of Class of Securities)

     

    09060J106

    (CUSIP Number)

     

     

    December 31, 2022
    (Date of Event Which Requires Filing of this Statement)

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

     

    o Rule 13d-1(b)

    x Rule 13d-1(c)

    o Rule 13d-1(d)

     

     

    *The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

     

    The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     


     

    CUSIP No.  09060J106
     SCHEDULE 13G/A
    Page 2 of 6 Pages

     

             
    1
    NAME OF REPORTING PERSONS
     
    Asset Management Exchange Master ICAV
    2
    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
    (a) o
    (b) o
     
    3
    SEC USE ONLY
     
     
    4
    CITIZENSHIP OR PLACE OF ORGANIZATION
     
    Ireland
    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON
    WITH
    5
    SOLE VOTING POWER
     
    0
    6
    SHARED VOTING POWER
     
    0
    7
    SOLE DISPOSITIVE POWER
     
    0
    8
    SHARED DISPOSITIVE POWER
     
    0
    9
    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
     
    0
    10
    CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES
     
     
    o
    11
    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
     
    0.0%
    12
    TYPE OF REPORTING PERSON
     
    OO

     


     

     

    CUSIP No. 09060J106
     SCHEDULE 13G/A
    Page 3 of 6 Pages

     

    Item 1.(a) Name of Issuer

    BioDelivery Sciences International, Inc.

    Item 1.(b) Address of Issuer’s Principal Executive Offices

    4131 ParkLake Ave., Suite 225

    Raleigh, NC 27612

     

    Item 2.(a, b, c) Names of Person Filing, Address of Principal Business Office, Citizenship:

    (a) Asset Management Exchange Master ICAV, c/o Carne Global Fund Managers (Ireland) Limited

    (b) 2nd Floor, Block E

    Iveagh Court

    Harcourt Road

    Dublin 2

    Ireland 

    (c) Ireland

      

    Item 2.(d) Title of Class of Securities

    Common stock, par value $0.001 (the “Common Stock”)

     

    Item 2.(e) CUSIP No.:

    09060J106

     

    CUSIP No.  09060J106
     SCHEDULE 13G/A
    Page 4 of 6 Pages

     

     

    Item 3. If this statement is filed pursuant to §§240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:

      (a) ¨ Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
     
      (b) ¨ Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
     
      (c) ¨ Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
     
      (d) ¨ Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
     
      (e) o An investment adviser in accordance with §240.13d-1(b)(1)(ii)(E);
     
      (f) ¨ An employee benefit plan or endowment fund in accordance with §240.13d-1(b)(1)(ii)(F);
     
      (g) ¨ A parent holding company or control person in accordance with §240.13d-1(b)(1)(ii)(G);
     
      (h) ¨ A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
     
      (i) ¨ A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
     
      (j) ¨ A non-U.S. institution in accordance with §240.13d-1(b)(1)(ii)(J);
     
      (k) ¨ A group, in accordance with §240.13d-1(b)(1)(ii)(K). If filing as a non-U.S. institution in accordance with §240.13d-1(b)(1)(ii)(J), please specify the type of institution:                            
           

     

    CUSIP No. 09060J106
     SCHEDULE 13G/A
    Page 5 of 6 Pages

     

     

    Item 4. Ownership

    Information with respect to the Reporting Persons' ownership of the Common Stock as of December 31, 2022, is incorporated by reference to items (5) - (9) and (11) of the cover page of the respective Reporting Person.

    Item 5. Ownership of Five Percent or Less of a Class

    If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following [X].

    Item 6. Ownership of More Than Five Percent on Behalf of Another Person

    Not Applicable.

    Item 7. Identification and Classification of the Subsidiary which Acquired the Security Being Reported on by the Parent Holding Company or Control Person

    Not Applicable.

    Item 8. Identification and Classification of Members of the Group

    Not Applicable.

    Item 9. Notice of Dissolution of Group 

    Not Applicable.

    Item 10. Certification

    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.

     

     
    CUSIP No. 09060J106
     SCHEDULE 13G/A
    Page 6 of 6 Pages

     

     

    SIGNATURE

     

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     

    Dated: February 10, 2023

     

     

     

     

    Asset Management Exchange Master ICAV

           
      By:  /s/ Andre Bruwer
        Andre Bruwer, Director
           
           

     

    Get the next $BDSI alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $BDSI

    DatePrice TargetRatingAnalyst
    2/15/2022$5.00 → $5.60Overweight → Neutral
    Piper Sandler
    1/21/2022$4.00 → $4.50Neutral
    HC Wainwright & Co.
    11/4/2021$6.00 → $4.50Buy → Neutral
    HC Wainwright & Co.
    8/5/2021$5.50 → $6.00Buy
    HC Wainwright & Co.
    More analyst ratings

    $BDSI
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G/A filed by BioDelivery Sciences International Inc. (Amendment)

      SC 13G/A - BIODELIVERY SCIENCES INTERNATIONAL INC (0001103021) (Subject)

      2/10/23 4:14:56 PM ET
      $BDSI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13D filed by BioDelivery Sciences International Inc.

      SC 13D - BIODELIVERY SCIENCES INTERNATIONAL INC (0001103021) (Subject)

      2/24/22 12:05:58 PM ET
      $BDSI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G filed by BioDelivery Sciences International Inc.

      SC 13G - BIODELIVERY SCIENCES INTERNATIONAL INC (0001103021) (Subject)

      2/24/22 11:06:16 AM ET
      $BDSI
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $BDSI
    Leadership Updates

    Live Leadership Updates

    See more
    • BioDelivery Sciences Appoints John Golubieski as Chief Financial Officer

      RALEIGH, N.C., Oct. 21, 2021 (GLOBE NEWSWIRE) -- BioDelivery Sciences International, Inc. (NASDAQ:BDSI), a rapidly growing commercial-stage specialty pharmaceutical company dedicated to patients living with chronic conditions, today announced the appointment of John Golubieski as Chief Financial Officer, effective November 4, 2021.  Mr. Golubieski brings to BDSI more than 30 years of financial and operational experience and will serve as a member of the company's executive leadership team. "I'm pleased to welcome John to our executive leadership team. His appointment comes at a time of significant opportunity and growth for BDSI," said Jeff Bailey, Chief Executive Officer. "I know first-h

      10/21/21 8:00:00 AM ET
      $BDSI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • AzurRx BioPharma Announces Appointment of Terry Coelho to its Board of Directors

      BOCA RATON, Fla., Aug. 16, 2021 (GLOBE NEWSWIRE) -- AzurRx BioPharma, Inc. ("AzurRx" or the "Company") (NASDAQ:AZRX), a company specializing in the development of targeted non-systemic, therapies for gastrointestinal (GI) diseases, today announced the appointment of Terry Coelho to its Board of Directors effective immediately. The appointment increases the size of AzurRx's Board to seven members. Ms. Coelho currently serves as the Executive Vice President and Chief Financial Officer at BioDelivery Sciences International, Inc. (NASDAQ:BDSI), a commercial-stage specialty pharmaceutical company. During her more than 30-year career, Ms. Coelho has held numerous senior level financial an

      8/16/21 8:00:00 AM ET
      $AZRX
      $BCPC
      $BDSI
      Major Pharmaceuticals
      Health Care
      Major Chemicals
      Industrials

    $BDSI
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • BioDelivery Sciences Intl downgraded by Piper Sandler with a new price target

      Piper Sandler downgraded BioDelivery Sciences Intl from Overweight to Neutral and set a new price target of $5.60 from $5.00 previously

      2/15/22 4:35:51 AM ET
      $BDSI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • HC Wainwright & Co. reiterated coverage on BioDelivery Sciences Intl with a new price target

      HC Wainwright & Co. reiterated coverage of BioDelivery Sciences Intl with a rating of Neutral and set a new price target of $4.50 from $4.00 previously

      1/21/22 6:26:41 AM ET
      $BDSI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • BioDelivery Sciences Intl downgraded by HC Wainwright & Co. with a new price target

      HC Wainwright & Co. downgraded BioDelivery Sciences Intl from Buy to Neutral and set a new price target of $4.50 from $6.00 previously

      11/4/21 7:12:11 AM ET
      $BDSI
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $BDSI
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Genenta Provides First Half 2022 Business Update and Financial Results

      Current dose escalation study data shows a median overall survival of 17 monthsAdding cohort to Phase 1/2a trial in GBM to assess additional conditioning regimenCash and cash equivalents of €34.7 million as of June 30, 2022, providing a cash runway until the end of 2024€1.8 million unrealized foreign exchange gain MILAN, Italy and NEW YORK, Oct. 24, 2022 (GLOBE NEWSWIRE) -- Genenta Science (NASDAQ:GNTA), ("Genenta" or the "Company"), a clinical stage immuno-oncology company developing a cell-based platform harnessing the power of hematopoietic stem cells to provide durable and safe treatments for solid tumors, provides business and financial results for the six months ended June 30, 2022.

      10/24/22 7:30:00 AM ET
      $GNTA
      $BDSI
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
      Biotechnology: Pharmaceutical Preparations
    • Genenta Announces Nomination of Mark A. Sirgo as Chair

      35 years industry experience including as CEO and founder of public company Stephen Squinto steps down as Chair for new role MILAN, Italy and NEW YORK, April 27, 2022 (GLOBE NEWSWIRE) -- Genenta Science (NASDAQ:GNTA), a clinical-stage biotechnology company pioneering the development of hematopoietic stem progenitor cell immuno-gene therapy for cancer, announced the nomination of Mark A. Sirgo, PharmD, an executive leader with over 35 years of pharmaceutical industry experience, as its new Chair. Stephen Squinto, PhD is stepping down from his role as Chair on May 1, 2022 to pursue a new business opportunity. Dr. Sirgo most recently was CEO of Aruna Bio, Inc., a preclinical biotech compan

      4/27/22 7:30:00 AM ET
      $BDSI
      $GNTA
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Biotechnology: Biological Products (No Diagnostic Substances)
    • Collegium Completes the Acquisition of BDSI

      STOUGHTON, Mass., March 22, 2022 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (NASDAQ:COLL) ("Collegium") today announced that it has completed the acquisition of BioDelivery Sciences International Inc. (NASDAQ:BDSI) ("BDSI"). "This acquisition is a major step forward in our mission to build a leading, diversified specialty pharmaceutical company committed to improving the lives of people living with serious medical conditions," said Joe Ciaffoni, President and Chief Executive Officer of Collegium. "We have significantly diversified the business and expanded our overall revenue scale. This transaction is immediately and highly accretive, and we are now focused on seamless integratio

      3/22/22 5:01:00 PM ET
      $BDSI
      $COLL
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $BDSI
    Financials

    Live finance-specific insights

    See more

    $BDSI
    SEC Filings

    See more
    • Collegium Completes the Acquisition of BDSI

      STOUGHTON, Mass., March 22, 2022 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (NASDAQ:COLL) ("Collegium") today announced that it has completed the acquisition of BioDelivery Sciences International Inc. (NASDAQ:BDSI) ("BDSI"). "This acquisition is a major step forward in our mission to build a leading, diversified specialty pharmaceutical company committed to improving the lives of people living with serious medical conditions," said Joe Ciaffoni, President and Chief Executive Officer of Collegium. "We have significantly diversified the business and expanded our overall revenue scale. This transaction is immediately and highly accretive, and we are now focused on seamless integratio

      3/22/22 5:01:00 PM ET
      $BDSI
      $COLL
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Collegium to Acquire BioDelivery Sciences Broadening Pain Portfolio

      - Expected to be Immediately and Highly Accretive Driven by Identified Annual Synergies of at Least $75 Million - - Will Diversify Revenue Growth and Accelerate Cash Flow Generation - - Addition of BELBUCA® Provides a Second Growth Driver and ELYXYB™ Establishes Foothold in Neurology - - Conference Call Scheduled for Today at 8:30 a.m. ET - STOUGHTON, Mass. and RALEIGH, N.C., Feb. 14, 2022 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (NASDAQ:COLL) and BioDelivery Sciences International, Inc. (NASDAQ:BDSI) today announced a definitive agreement pursuant to which Collegium will acquire BDSI for $5.60 per share in cash. BDSI has a portfolio of pain and neurology products that addre

      2/14/22 6:30:00 AM ET
      $BDSI
      $COLL
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • BioDelivery Sciences Reports Solid Third Quarter 2021 Results

      Total Net Revenue of $41.1 Million, an Increase of 4% versus Prior Year Strong profitability with GAAP EPS of $0.07, EBITDA Margin of 27% and $7.0 million Operating Cash Flow Closed acquisition of ELYXYB, the first FDA-approved, ready-to-use oral solution for acute migraine with potential long-term peak sales opportunity of $350 - $400 million Conference Call and Webcast Scheduled for 8:30 AM EST Today RALEIGH, N.C., Nov. 03, 2021 (GLOBE NEWSWIRE) -- BioDelivery Sciences International, Inc. (NASDAQ:BDSI), a growing specialty pharmaceutical company dedicated to patients living with serious and complex chronic conditions, today reported solid financial results for the third quarter ended

      11/3/21 8:00:00 AM ET
      $BDSI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 15-12B filed by BioDelivery Sciences International Inc.

      15-12B - BIODELIVERY SCIENCES INTERNATIONAL INC (0001103021) (Filer)

      4/1/22 5:02:37 PM ET
      $BDSI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form EFFECT filed by BioDelivery Sciences International Inc.

      EFFECT - BIODELIVERY SCIENCES INTERNATIONAL INC (0001103021) (Filer)

      3/28/22 12:15:08 AM ET
      $BDSI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form S-8 POS filed by BioDelivery Sciences International Inc.

      S-8 POS - BIODELIVERY SCIENCES INTERNATIONAL INC (0001103021) (Filer)

      3/23/22 5:30:38 PM ET
      $BDSI
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $BDSI
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4: Watson W. Mark disposed of 90,663 shares, closing all direct ownership in the company to satisfy tax liability

      4 - BIODELIVERY SCIENCES INTERNATIONAL INC (0001103021) (Issuer)

      3/22/22 5:18:46 PM ET
      $BDSI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Vollins James (withholding tax)

      4 - BIODELIVERY SCIENCES INTERNATIONAL INC (0001103021) (Issuer)

      3/22/22 5:18:09 PM ET
      $BDSI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4: Singh Vanila disposed of 35,851 shares, closing all direct ownership in the company to satisfy withholding tax

      4 - BIODELIVERY SCIENCES INTERNATIONAL INC (0001103021) (Issuer)

      3/22/22 5:17:22 PM ET
      $BDSI
      Biotechnology: Pharmaceutical Preparations
      Health Care